https://www.globenewswire.com/fr/news-release/2017/09/22/1131482/28291/en/Melinta-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences.html
NEW HAVEN, Conn., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to...
melinta therapeuticsparticipatetwoupcoming
https://www.businesswire.com/news/home/20210429005287/en/Melinta-Therapeutics-and-Hikma-Sign-Exclusive-Licensing-Agreement-for-Two-Novel-Anti-Infectives-for-the-Middle-East-and-North-Africa-Region
Melinta Therapeutics and Hikma sign exclusive licensing agreement for two novel anti-infectives for the Middle East and North Africa region.
melinta therapeuticsexclusive licensinghikmasignagreement
https://www.globenewswire.com/fr/news-release/2017/09/25/1132077/28291/en/Melinta-Therapeutics-Presenting-Detailed-Analyses-from-Baxdela-Phase-3-ABSSSI-Trials-and-In-Vitro-Performance-against-Isolates-of-Resistant-CABP-and-other-Infections.html
NEW HAVEN, Conn., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to...
melinta therapeuticspresentingdetailedanalyses